The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 03, 2006

Filed:

Jun. 19, 2003
Applicants:

Lawrence A. Black, Libertyville, IL (US);

Anwer Basha, Lake Forest, IL (US);

Teodozyj Kolasa, Lake Villa, IL (US);

Michael E. Kort, Lake Bluff, IL (US);

Huaqing Liu, Buffalo Grove, IL (US);

Catherine M. Mccarty, Brookline, MA (US);

Meena Patel, Chicago, IL (US);

Jeffrey J. Rohde, Evanston, IL (US);

Michael J. Coghlan, Grayslake, IL (US);

Andrew O. Stewart, Libertyville, IL (US);

Inventors:

Lawrence A. Black, Libertyville, IL (US);

Anwer Basha, Lake Forest, IL (US);

Teodozyj Kolasa, Lake Villa, IL (US);

Michael E. Kort, Lake Bluff, IL (US);

Huaqing Liu, Buffalo Grove, IL (US);

Catherine M. McCarty, Brookline, MA (US);

Meena Patel, Chicago, IL (US);

Jeffrey J. Rohde, Evanston, IL (US);

Michael J. Coghlan, Grayslake, IL (US);

Andrew O. Stewart, Libertyville, IL (US);

Assignee:

Abbott Laboratories, Abbott Park, IL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/50 (2006.01); A61K 31/675 (2006.01); C07D 237/16 (2006.01); C07F 9/6509 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention describes pyridazinone compounds of formula I which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2), COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important 'housekeeping' enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently markered non-steroidal anti-inflammatory drugs (NSAIDs).


Find Patent Forward Citations

Loading…